Literature DB >> 17022050

Biochemical markers of bone turnover in diagnosis of myeloma bone disease.

Omer Dizdar1, Ibrahim Barista, Umut Kalyoncu, Omer Karadag, Gulsen Hascelik, Aysenur Cila, Asli Pinar, Ismail Celik, Ayse Kars, Gulten Tekuzman.   

Abstract

This study was designed to explore the value of markers of bone turnover, macrophage inflammatory protein-1alpha (MIP-1alpha), and osteopontin (OPN) in the diagnosis of myeloma bone disease. Twenty-five patients with newly diagnosed and untreated multiple myeloma (MM), and 22 age-, sex-, and bone mineral density-matched control subjects were enrolled. Levels of MIP-1alpha, OPN, carboxy-terminal telopeptide of Type-1 collagen (C-telopeptide or Ctx), deoxypyridinoline (DPD), Type-1 collagen propeptide (T1Pro), and bone-specific alkaline phosphatase (BALP) were assessed in both groups. Twenty-two of the patients had bone involvement documented by skeletal surveys and lumbar spinal magnetic resonance imaging. Levels of serum Ctx, OPN, MIP-1alpha, and urine DPD were significantly higher in MM patients with bone disease than in controls (P<0.01). Serum Ctx levels were elevated in 90.9% of patients with MM and 40.9% of controls (P<0.001). Urine DPD levels were elevated in 90.4% of the patients and 31.8% of the controls (P<0.001). The serum OPN and MIP-1alpha levels of the patients were significantly correlated with beta2-microglobulin and lactate dehydrogenase levels (P<0.05). Our study indicates that Ctx and DPD are sensitive markers of bone disease in MM, and higher than normal values suggest presence of bone disease rather than benign osteoporosis in MM. The utility of OPN and MIP-1alpha needs to be further investigated. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17022050     DOI: 10.1002/ajh.20794

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors: 
Journal:  Am J Hematol       Date:  2018-08-16       Impact factor: 10.047

2.  Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2012-01       Impact factor: 10.047

3.  Osteolytic lesions marker in multiple myeloma.

Authors:  Irena Djunic; Ivo Elezovic; Milica Marinkovic; Nada Suvajdzic-Vukovic; Dragica Tomin; Gradimir Jankovic; Jelena Bila; Darko Antic; Ana Vidovic; Borka Neskovic; Dragica Nikolic-Vukosavljevic
Journal:  Med Oncol       Date:  2010-02-02       Impact factor: 3.064

4.  Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2022-05-23       Impact factor: 13.265

Review 5.  Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-07       Impact factor: 10.047

6.  Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.

Authors:  Paul Dowling; Catriona Hayes; Kay Reen Ting; Abdul Hameed; Justine Meiller; Constantine Mitsiades; Kenneth C Anderson; Martin Clynes; Colin Clarke; Paul Richardson; Peter O'Gorman
Journal:  BMC Genomics       Date:  2014-10-17       Impact factor: 3.969

7.  Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma.

Authors:  Toni Valković; Emina Babarović; Ksenija Lučin; Sanja Štifter; Merica Aralica; Sanja Pećanić; Irena Seili-Bekafigo; Antica Duletić-Načinović; Damir Nemet; Nives Jonjić
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

8.  Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation.

Authors:  Peter W Schreiber; Heike A Bischoff-Ferrari; Katia Boggian; Marco Bonani; Christian van Delden; Natalia Enriquez; Thomas Fehr; Christian Garzoni; Hans H Hirsch; Cédric Hirzel; Oriol Manuel; Pascal Meylan; Lanja Saleh; Maja Weisser; Nicolas J Mueller
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.